Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Curis LifesciencesNSE:CURIS 19 EPS without NRI is ₹37.14 as of Mar. 2026. GuruFocus rates NSE:CURIS with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 788 Drug Manufacturers companies, Curis Lifesciences ranks better than 99.24% on this metric.
Curis Lifesciences's earnings per share without non-recurring items for the
six
months ended in Mar. 2026 was ₹37.14.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was ₹37.14.
During the past 12 months, Curis Lifesciences's average earnings per share (NRI) Growth Rate was 10.90% per year.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 182.30% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Curis Lifesciences's EPS without NRI or its related term are showing as below:
NSE:CURIS'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 182.3 Med: 182.3 Max: 182.3
Current: 182.3
During the past 4 years, Curis Lifesciences's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 182.30% per year. The lowest was 182.30% per year. And the median was 182.30% per year.
NSE:CURIS's 3-Year EPS without NRI Growth Rate is ranked better than 99.24% of 788
companies
in the Drug Manufacturers industry
Industry Median: 9.6
vs NSE:CURIS: 182.30
Curis Lifesciences's EPS (Basic) for the
six
months ended in Mar. 2026 was ₹37.14.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹37.14.
Curis Lifesciences (NSE:CURIS) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Curis Lifesciences EPS without NRI Related Terms
Curis Lifesciences EPS without NRI Historical Data
* Premium members only.
The historical data trend for Curis Lifesciences's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis Lifesciences EPS without NRI Chart
Curis Lifesciences Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
EPS without NRI
1.65
6.38
33.50
37.14
Curis Lifesciences Semi-Annual Data
Mar23
Mar24
Mar25
Mar26
EPS without NRI
1.65
6.38
33.50
37.14
NSE:CURIS vs ZTS: EPS without NRI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Curis Lifesciences's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curis Lifesciences PE Ratio without NRI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curis Lifesciences's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Curis Lifesciences's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
For stock reported annually, GuruFocus uses latest annual data as the TTM data. EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was ₹37.14
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis Lifesciences (NSE:CURIS) has a EPS without NRI of ₹37.14 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Curis Lifesciences and its competitors. According to the industry distribution chart, Curis Lifesciences ranks #6 out of 788 companies in the Drug Manufacturers industry, placing it in the top 0.8%.
Is Curis Lifesciences' EPS without NRI too high?
Curis Lifesciences' current EPS without NRI is ₹37.14. Based on the distribution chart, Curis Lifesciences ranks #6 out of 788 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Curis Lifesciences has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Curis Lifesciences' EPS without NRI compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Curis Lifesciences ranks #6 out of 788 companies for EPS without NRI. This places Curis Lifesciences in the top 1% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.60, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Curis Lifesciences and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curis Lifesciences's current EPS without NRI is ₹37.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curis Lifesciences stock overvalued right now?
Curis Lifesciences (NSE:CURIS) has a current EPS without NRI of ₹37.14. The current EPS without NRI is ₹37.14. Curis Lifesciences' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Curis Lifesciences (NSE:CURIS), the current EPS without NRI is ₹37.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curis Lifesciences Ltd is in the business of manufacturing of pharmaceutical products. It specializes in the manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral liquid, and Sterile Ophthalmic Ointments. The company's business verticals are: Loan License manufacturing, Contract Manufacturing, and Direct Export. The company derives revenue from the sale of its pharmaceutical products.
19GF Score
Get the complete analysis for NSE:CURIS
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CURIS has been successfully added to your 
